commented on two gd T cell papers recently published in Immunity (Martin et al., 2009; Sutton et al., 2009 ) and raise a number of questions. We are responding to those that apply to our paper (Martin et al., 2009) .
The main focus of our paper was the demonstration that a subset of gd T cells (CCR6 + ) shares characteristic features with T helper 17 (Th17) cells and that these can respond to specific Toll-like receptor (TLR) ligands with the production of interleukin-17 (IL-17) even without the interaction with antigen-presenting cells providing IL-23. Nowhere in our paper do we claim that we are the first to show gd T cells can produce IL-17 without deliberate stimulation via the TLR. In fact we say: ''This does not preclude a role of TCR and our studies do not allow the conclusion that TLR triggers act in isolation.'' We are aware that a wide range of signals, including stress-induced signals could activate the TCR on gd T cells so that it is virtually impossible to exclude TCR triggering. As mentioned in our paper, IL-17-producing gd T cells have an activated phenotype already when isolated ex vivo, suggesting prior TCRmediated activation. We also clearly state in the Discussion the following: ''For the in vitro experiments showing functional effects of TLR ligands, we FACS sorted gd T cells by using antibodies directed against the T cell receptor that most likely causes activation, and the injection of pure TLR ligands in vivo cannot exclude simultaneous TCR triggers by potential endogenous ligands.''
We have cited the paper by Shibata et al. (2007) , which is relevant regarding IL-17 production by gd T cells, whereas the paper by Cheng et al. (2008) does not really focus on this issue and was therefore not included.
Regarding the identification of the IL-17 producing subset, we agree with O'Brien et al. that there are differences in representation of Vg2 (called Vg4 by Heilig and Tonegawa, 1986) and Vg1 subsets after intraperitoneal versus subcutaneous injection. However, these are subtle alterations in ratios and both subsets contain IL-17 producers. The confusion with different nomenclatures in the gd T cell field does not help, but we are certainly not comparing oranges with apples. First, we show in our paper ( Figure 1D in Martin et al., 2009 ) the distribution of IL-17 producers in peripheral lymph nodes from unimmunized mice-there is no CFA injection involved here. Most IL-17 producers in the lymph nodes are Vg2 (Vg4 in Tonegawa nomenclature) and a few are Vg1. There is a subset of Vg1.2 (probably those that are called Vg4ÀVg1À by O'Brien et al.) for which there is no commercially available antibody-this accounts for the $25% missing proportion of cells in Figure 1D (Martin et al., 2009) . None of the other Vg subsets are found in substantial numbers in peripheral lymphoid organs.
We have not shown Vg allocations for immunized mice in this paper, but we find that draining lymph nodes from CFA immunized mice analyzed between 3 hr and 48 hr afterward are 80% Vg2 (the proportional representation of different Vg subsets is not stated in the Figure S1 shown by O'Brien et al., 2010) .
PEC from mice immunized with heatkilled mycobacteria (we are not authorized to inject CFA i.p.) analyzed 12 hr later have a somewhat reduced proportion of Vg2 cells (60% instead of 80% as in resting lymph nodes from unimmunized mice), but the remainder expresses IL-17 and the associated program to the same extent. As we state in our paper: Figure 1D in our paper. Vg6 cells, called Vg4 in the Garman nomenclature that we have used (Garman et al., 1986) , are the prominent subset found in the lung and are not present in the peritoneal cavity. All in all, the objections raised by O'Brien et al. regarding our paper seem to be based on a number of misunderstandings.
